Substituted pyridotriazole compound, and preparation method therefor and use thereof

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
By developing novel structured RIPK1 kinase inhibitors, the problem of difficulty in effectively inhibiting RIPK1 and MLK kinase in the prior art has been solved, and effective treatment of cell programmed necrosis-related diseases has been achieved.

WO2025060911A1 Publication Date: 2025-03-27ORIGIANT PHARM CO LTD

5 Cites 0 Cited by

Patent Information

Application Number: PCT/CN2024/117673
Authority / Receiving Office: WO · WO
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-07-12
Filing Date: 2024-09-09
Publication Date: 2025-03-27

Application Information

Patent Timeline

12 Jul 2024

Priority

09 Sep 2024

Application

PCT/CN2024/117673

27 Mar 2025

Publication

WO2025060911A1

IPC: C07D471/04; C07D519/00; A61K31/437; A61K31/5377; A61K31/4545; A61K31/438; A61P35/00; A61P37/06; A61P25/28; A61P29/00

CPC: C07D471/04; C07D519/00; A61P35/00; A61P37/06; A61P25/28; A61P29/00; C07D401/14; C07D498/04

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Application Domain

Organic active ingredients Nervous disorder

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit RIPK1 and MLK kinase, resulting in poor therapeutic effects on cell programmed necrosis-related diseases.

Method used

A class of novel structural inhibitors of RIPK1 kinase were developed, which can effectively inhibit the activities of RIPK1 and MLK kinases through specific compound structure design.

Benefits of technology

These inhibitors can significantly inhibit the activity of RIPK1 and MLK, thereby reducing the occurrence of programmed cell necrosis, and provide potential treatment options such as для inflammation, autoimmune diseases, neurodegenerative diseases and tumors.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

The present invention relates to the technical field of medicine, in particular to a substituted pyridotriazole compound, and a preparation method therefor and the use thereof. Disclosed in the description are a substituted pyridotriazole compound having an inhibitory effect on RIPK1 and / or MLK, and a pharmaceutically acceptable salt, a stereoisomer, a solvent or a prodrug thereof. The compound is as shown in formula (I), and the definition of each group in the formula is as described in detail in the description. In addition, further disclosed in the present invention are a pharmaceutical composition comprising the compound and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.

Need to check novelty before this filing date? Find Prior Art